reports
Pharvaris Presents Data Highlighting the Potential for Deucrictibant t...
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Cli...
Pharvaris Announces Annual Meeting of Shareholders
Pharvaris Announces Annual Meeting of Shareholders ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). All relevant documents and information relating to the annual ...
- Wedbush Research
- Jacob Mekhael
Pharvaris R&D day outlines plans to expand deucrictibant opportunity
Yesterday, Pharvaris hosted an R&D call to discuss plans for deucrictibant (oral B2 receptor antagonist) beyond HAE type 1/2. The company believes that deucrictibant could offer good outcomes for patients with normal C1-INH HAE, and this subset of patients is included in the phase 3 programs for on-demand and prophylaxis. In addition, the company pointed to the potential of deucrictibant to address acquired angioedema (AAE), where no approved treatments exist and investigator results demonstrate...
- Dylan Shindler
- Laura Chico
- Jacob Mekhael
Pharvaris Supportive data at C1-Inhibitor Deficiency and Angioedema Wo...
Pharvaris provided a summary of data that was presented at the C1-Inhibitor Deficiency and Angioedema Workshop, held 29 May – 1 June. The presentations continue to be supportive of deucrictibant's differentiated profile in HAE and included i) data that supports dual use of B2 antagonism for LTP and ODT in the same patients, ii) limited symptom recurrence showing durability of on-demand treatment, as well as iii) a novel biomarker assay that could help identify BK mediated angioedema. We reiterat...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deu...
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treatedFirst-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolioClinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-mediated angioedemaEpidemiologic data and cognitive interviews further elucidate the un...
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Bioma...
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Worksh...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Wedbush Research
- Jacob Mekhael
Pharvaris 1Q25 shows continued pipeline progress, upcoming R&D call in...
Pharvaris reported 1Q25 results with a cash position of € 236m (YE24: € 281m), which provides a cash runway into 3Q26. Pipeline-wise, the company continues to progress with its phase 3 trials in both HAE on-demand and prophylaxis, and confirms the previously communicated timelines, with the next key milestone being topline results from the phase 3 trial of deucrictibant in on-demand HAE in 1Q26. We note that an FDA waiver for thorough QT study requirements provides further validation of deucrict...
- Dylan Shindler
- Laura Chico
Pharvaris Reports First Quarter 2025 Financial Results and Provides Bu...
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesTQT study waivers received from FDA for both deucrictibant extended-release formulation and deucrictibant immediate-release formulationPharvaris Management to host R&D call on June 4 at 8:00 a...
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1...
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema ZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE), including HAE with normal C1 inhibitor and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
Pharvaris Initiation: A new pill's on the way to keep the swelling at ...
Pharvaris is a Dutch biotech developing deucrictibant for HAE, a rare genetic disease with a $3bn market, in both the on-demand and prophylactic settings. We see Pharvaris as an attractive investment case underpinned by deucrictibant's de-risked B2R target, competitive phase 2 results setting it up to be the only high efficacy oral option, in addition to a validated commercial opportunity for more convenient orals as evidenced by competitor Orladeyo's successful launch despite sub-par efficacy. ...
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results ...
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Orphan medicinal product designation granted to deucrictibant in Europe for the treatment of bradykinin-mediated angioedemaData presented at recent congresses reinforces the value of deucri...
- Dylan Shindler
- Laura Chico
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the...
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykini...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.